nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—SLC6A3—attention deficit hyperactivity disorder	0.467	0.572	CbGaD
Escitalopram—SLC6A4—attention deficit hyperactivity disorder	0.349	0.428	CbGaD
Escitalopram—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0109	0.212	CbGeAlD
Escitalopram—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00577	0.113	CbGeAlD
Escitalopram—Citalopram—SLC6A3—attention deficit hyperactivity disorder	0.00402	0.572	CrCbGaD
Escitalopram—Citalopram—SLC6A4—attention deficit hyperactivity disorder	0.003	0.428	CrCbGaD
Escitalopram—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00167	0.0326	CbGeAlD
Escitalopram—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00161	0.0315	CbGeAlD
Escitalopram—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00153	0.0298	CbGeAlD
Escitalopram—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00152	0.0297	CbGeAlD
Escitalopram—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00134	0.0263	CbGeAlD
Escitalopram—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.00129	0.0251	CbGeAlD
Escitalopram—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00125	0.0244	CbGeAlD
Escitalopram—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.0011	0.0215	CbGeAlD
Escitalopram—HTR2C—midbrain—attention deficit hyperactivity disorder	0.00106	0.0208	CbGeAlD
Escitalopram—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00106	0.0207	CbGeAlD
Escitalopram—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.00101	0.0197	CbGeAlD
Escitalopram—HRH1—forebrain—attention deficit hyperactivity disorder	0.000968	0.0189	CbGeAlD
Escitalopram—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000905	0.0177	CbGeAlD
Escitalopram—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000875	0.0171	CbGeAlD
Escitalopram—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000871	0.017	CbGeAlD
Escitalopram—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000852	0.0166	CbGeAlD
Escitalopram—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000842	0.0165	CbGeAlD
Escitalopram—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000829	0.0162	CbGeAlD
Escitalopram—CHRM1—nervous system—attention deficit hyperactivity disorder	0.000826	0.0161	CbGeAlD
Escitalopram—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000798	0.0156	CbGeAlD
Escitalopram—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000795	0.0155	CbGeAlD
Escitalopram—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000736	0.0144	CbGeAlD
Escitalopram—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.00073	0.0143	CbGeAlD
Escitalopram—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000703	0.0137	CbGeAlD
Escitalopram—SLC6A3—brain—attention deficit hyperactivity disorder	0.000692	0.0135	CbGeAlD
Escitalopram—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000679	0.0133	CbGeAlD
Escitalopram—HTR2C—brain—attention deficit hyperactivity disorder	0.000669	0.0131	CbGeAlD
Escitalopram—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000653	0.0128	CbGeAlD
Escitalopram—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000639	0.0125	CbGeAlD
Escitalopram—SLC6A4—brain—attention deficit hyperactivity disorder	0.000634	0.0124	CbGeAlD
Escitalopram—CHRM1—brain—attention deficit hyperactivity disorder	0.000631	0.0123	CbGeAlD
Escitalopram—SLC6A2—brain—attention deficit hyperactivity disorder	0.000558	0.0109	CbGeAlD
Escitalopram—HRH1—nervous system—attention deficit hyperactivity disorder	0.000525	0.0103	CbGeAlD
Escitalopram—ADRA1A—brain—attention deficit hyperactivity disorder	0.000519	0.0101	CbGeAlD
Escitalopram—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000506	0.00988	CbGeAlD
Escitalopram—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000406	0.00794	CbGeAlD
Escitalopram—HRH1—brain—attention deficit hyperactivity disorder	0.000402	0.00785	CbGeAlD
Escitalopram—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.0004	0.00781	CbGeAlD
Escitalopram—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000391	0.00764	CbGeAlD
Escitalopram—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000385	0.00752	CbGeAlD
Escitalopram—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000376	0.00735	CbGeAlD
Escitalopram—CYP2D6—brain—attention deficit hyperactivity disorder	0.000306	0.00597	CbGeAlD
Escitalopram—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000106	0.000841	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000106	0.00084	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000105	0.000835	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000104	0.000827	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000103	0.000816	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000103	0.000813	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000102	0.000806	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000101	0.0008	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000101	0.000798	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0001	0.000795	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	9.88e-05	0.000783	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.76e-05	0.000773	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.72e-05	0.00077	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	9.63e-05	0.000763	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.59e-05	0.000759	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.57e-05	0.000758	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.56e-05	0.000757	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.52e-05	0.000754	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	9.51e-05	0.000753	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.47e-05	0.00075	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.44e-05	0.000748	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.44e-05	0.000748	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.41e-05	0.000745	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.41e-05	0.000745	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	9.33e-05	0.000739	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	9.3e-05	0.000737	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.29e-05	0.000736	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.26e-05	0.000734	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	9.16e-05	0.000725	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.07e-05	0.000718	CbGpPWpGaD
Escitalopram—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	8.95e-05	0.000709	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.88e-05	0.000703	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.85e-05	0.000701	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.82e-05	0.000699	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.79e-05	0.000696	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.66e-05	0.000686	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.57e-05	0.000679	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.43e-05	0.000667	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	8.35e-05	0.000661	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.32e-05	0.000659	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.32e-05	0.000659	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	8.32e-05	0.000659	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.25e-05	0.000653	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.23e-05	0.000652	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.22e-05	0.000651	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	8.19e-05	0.000648	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.1e-05	0.000641	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.07e-05	0.000639	CbGpPWpGaD
Escitalopram—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.96e-05	0.00063	CbGpPWpGaD
Escitalopram—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.9e-05	0.000626	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.86e-05	0.000622	CbGpPWpGaD
Escitalopram—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.85e-05	0.000622	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.83e-05	0.00062	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	7.77e-05	0.000615	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.75e-05	0.000614	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.71e-05	0.00061	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.7e-05	0.000609	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.67e-05	0.000608	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.67e-05	0.000607	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.65e-05	0.000606	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	7.58e-05	0.0006	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.55e-05	0.000598	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.53e-05	0.000596	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.43e-05	0.000588	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.41e-05	0.000586	CbGpPWpGaD
Escitalopram—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.32e-05	0.00058	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.3e-05	0.000578	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.29e-05	0.000577	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.28e-05	0.000576	CbGpPWpGaD
Escitalopram—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.27e-05	0.000576	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.25e-05	0.000574	CbGpPWpGaD
Escitalopram—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.22e-05	0.000572	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.21e-05	0.000571	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.21e-05	0.000571	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.19e-05	0.000569	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.19e-05	0.000569	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.17e-05	0.000567	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.13e-05	0.000565	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.13e-05	0.000565	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.11e-05	0.000563	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.08e-05	0.00056	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.08e-05	0.00056	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7e-05	0.000554	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.99e-05	0.000553	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.97e-05	0.000552	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.86e-05	0.000543	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.72e-05	0.000532	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.7e-05	0.00053	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.59e-05	0.000522	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.28e-05	0.000498	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.26e-05	0.000496	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.18e-05	0.000489	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.17e-05	0.000488	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.16e-05	0.000488	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.16e-05	0.000488	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.06e-05	0.00048	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.66e-05	0.000448	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.59e-05	0.000443	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.43e-05	0.00043	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.38e-05	0.000426	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.33e-05	0.000422	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.32e-05	0.000421	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.23e-05	0.000415	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5e-05	0.000396	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.91e-05	0.000388	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.89e-05	0.000387	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.89e-05	0.000387	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.86e-05	0.000385	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.85e-05	0.000384	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.84e-05	0.000384	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.83e-05	0.000382	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.81e-05	0.000381	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.79e-05	0.000379	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.76e-05	0.000377	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.76e-05	0.000377	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.75e-05	0.000376	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.75e-05	0.000376	CbGpPWpGaD
Escitalopram—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.72e-05	0.000374	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.71e-05	0.000373	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.7e-05	0.000372	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.69e-05	0.000371	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.67e-05	0.00037	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.66e-05	0.000369	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	4.65e-05	0.000368	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.65e-05	0.000368	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.62e-05	0.000366	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.58e-05	0.000362	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.54e-05	0.00036	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.4e-05	0.000348	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.38e-05	0.000347	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.33e-05	0.000343	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.32e-05	0.000342	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.32e-05	0.000342	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.27e-05	0.000338	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.25e-05	0.000337	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.23e-05	0.000335	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.22e-05	0.000334	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.21e-05	0.000334	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.2e-05	0.000333	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.2e-05	0.000332	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.18e-05	0.000331	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.16e-05	0.000329	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.14e-05	0.000327	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.13e-05	0.000327	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.13e-05	0.000327	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.12e-05	0.000326	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.12e-05	0.000326	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.11e-05	0.000326	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.08e-05	0.000323	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.06e-05	0.000322	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.05e-05	0.000321	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.05e-05	0.000321	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.05e-05	0.000321	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.04e-05	0.00032	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4e-05	0.000317	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.98e-05	0.000315	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.97e-05	0.000315	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.94e-05	0.000312	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.92e-05	0.000311	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.86e-05	0.000306	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.81e-05	0.000302	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.8e-05	0.000301	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.8e-05	0.000301	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.78e-05	0.0003	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.75e-05	0.000297	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.74e-05	0.000296	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.74e-05	0.000296	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.73e-05	0.000295	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.7e-05	0.000293	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.69e-05	0.000292	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.68e-05	0.000291	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.63e-05	0.000288	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.45e-05	0.000273	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.44e-05	0.000272	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.38e-05	0.000268	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.3e-05	0.000262	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.26e-05	0.000258	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.07e-05	0.000243	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.99e-05	0.000237	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.89e-05	0.000229	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.86e-05	0.000227	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.85e-05	0.000226	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.81e-05	0.000222	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.79e-05	0.000221	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.68e-05	0.000213	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.66e-05	0.000211	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.65e-05	0.00021	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.61e-05	0.000207	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.6e-05	0.000206	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.55e-05	0.000202	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.52e-05	0.0002	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.5e-05	0.000198	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.49e-05	0.000197	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.45e-05	0.000194	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.41e-05	0.000191	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.41e-05	0.000191	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.37e-05	0.000188	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.35e-05	0.000186	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.33e-05	0.000184	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.32e-05	0.000184	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.28e-05	0.000181	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.25e-05	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	2.25e-05	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.25e-05	0.000178	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.24e-05	0.000178	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.19e-05	0.000173	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.18e-05	0.000173	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.17e-05	0.000172	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.15e-05	0.00017	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.07e-05	0.000164	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.07e-05	0.000164	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.06e-05	0.000163	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.04e-05	0.000161	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.03e-05	0.000161	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.03e-05	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2e-05	0.000158	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.96e-05	0.000155	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.89e-05	0.00015	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.8e-05	0.000142	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	0.000135	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.65e-05	0.000131	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.65e-05	0.00013	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.57e-05	0.000125	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.43e-05	0.000113	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.42e-05	0.000113	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.4e-05	0.000111	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	1.36e-05	0.000108	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	1.35e-05	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.35e-05	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.35e-05	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.33e-05	0.000105	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.31e-05	0.000104	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.25e-05	9.92e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.24e-05	9.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.24e-05	9.79e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.08e-05	8.55e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.03e-05	8.14e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.72e-06	6.91e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.19e-06	6.48e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.13e-06	6.44e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.56e-06	5.99e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.53e-06	5.97e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.42e-06	5.87e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	5.84e-06	4.62e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	5.37e-06	4.25e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.51e-06	2.78e-05	CbGpPWpGaD
